banner
3'-Az-ddU for nucleotide synthesis
Inquiry

Cat. No.: X24-04-QCY217

3'-Az-ddU for nucleotide synthesis

Synonym: 84472-85-5; Navuridine; AZddU; Uridine, 3'-azido-2',3'-dideoxy-; NSC-380882; PS28W65479; AzUrd; CHEMBL591804; 3'-azido-2',3'dideoxyuridine; SCHEMBL15531699; AKOS040744855; MS-23568; NS00122876; A855471; Uridine, 3'-azido-2',3'-dideoxy- and JPS-783; Q27286725; 1-(3-Azido-2,3-dideoxypentofuranosyl)-4-hydroxypyrimidin-2(1H)-one

  • MDL: MFCD00870324
  • CAS Number: 84472-85-5
  • Compound CID: 55262
img
Product Size
5 mg; 10 mg; 50 mg; 100 mg; 200 mg
Price
Datasheet
MSDS
Properties
Description
3'-Az-ddU is a reverse transcription inhibitor containing an Az group anchored to the 3' position of uracil, giving it a specific effect in inhibiting reverse transcriptase.
Molecular Weight
253.21
Molecular Formula
C9H11N5O4
Form
Powder
Purity
≥98%
Identity
Confirmed by NMR/HPLC/MS.
Applications
3'-Az-ddU can be used in the development of anti-HIV drugs and research on mechanisms of viral replication, gene transcription, and DNA strand elongation.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0